Revision: Dec. 20, 2017, 1:18 p.m.
SB 477 - AS INTRODUCED
2018 SESSION
18-3017
01/10
SENATE BILL 477
AN ACT establishing a therapeutic cannabis medical oversight board.
SPONSORS: Sen. Fuller Clark, Dist 21; Sen. Bradley, Dist 3; Sen. Watters, Dist 4; Sen. Reagan, Dist 17; Rep. Kotowski, Merr. 24; Rep. Knirk, Carr. 3
COMMITTEE: Health and Human Services
-----------------------------------------------------------------
ANALYSIS
This bill establishes the therapeutic cannabis medical oversight board to monitor the clinical, public health, and consumer related matters of the use of cannabis for therapeutic purposes law under RSA 126-X.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
18-3017
01/10
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Eighteen
AN ACT establishing a therapeutic cannabis medical oversight board.
Be it Enacted by the Senate and House of Representatives in General Court convened:
1 New Paragraph; Use of Cannabis for Therapeutic Purposes; Definitions. Amend RSA 126-X:1 by inserting after paragraph II the following new paragraph:
II-a. "Board" means the therapeutic cannabis medical oversight board established in RSA 126-X:12.
2 Use of Cannabis for Therapeutic Purposes; Definitions. Amend RSA 126-X:1, IX (b) to read as follows:
(b) The [department] board may include a medical condition that is not listed in subparagraph (a) that the department determines, on a case by case basis, is severely debilitating or terminal, based upon the written request of a provider who furnishes written certification to the [department] board.
3 New Paragraph; Use of Cannabis for Therapeutic Purposes; Rules. Amend RSA 126-X:6 by inserting after paragraph III the following new paragraph:
IV. The department shall adopt rules relative to the board's public hearing process pursuant to RSA 126-X:12, IV.
4 New Section; Use of Cannabis for Therapeutic Purposes; Therapeutic Cannabis Medical Oversight Board. Amend RSA 126-X by inserting after section 11 the following new section:
126-X:12 Therapeutic Cannabis Medical Oversight Board Established; Membership; Duties.
I. There is herby established the therapeutic cannabis medical oversight board which shall be responsible for the oversight of the clinical, public health, and consumer related matters of the use of cannabis for therapeutic purposes under this chapter.
II. The board shall consist of the medical director, department of health and human services, and 8 medical providers appointed by the commissioner of the department. The members shall represent the following fields:
(a) Neurology.
(b) Pain management.
(c) Oncology.
(d) Psychiatry.
(e) Pediatrics.
(f) Family Medicine.
(g) Obstetrics and Gynecology.
(h) Addiction.
III. At its first meeting the board shall elect by majority vote a chairperson and an alternate.
IV. The board shall convene at least 4 times per year to monitor the clinical, public health and safety, and quality outcomes and measures of therapeutic cannabis under this chapter by:
(a) Reviewing medical and scientific evidence pertaining to currently approved. and additional qualifying conditions.
(b) Reviewing laboratory results of required testing of cannabis cultivated and/or processed by an alternative treatment center and the use of pesticides on products under RSA 126-X:6, III(a)(16).
(c) Reviewing safety and packaging requirements, including levels of THC, of cannabis-infused products.
(d) Analyzing the efficacy of the programs and monitoring clinical outcomes.
(e) Reviewing training protocols for dispensary staff.
(f) Receiving updates from alternative treatment centers on effectiveness of strains for specific conditions.
(g) Reviewing any other clinical, quality, consumer and/or public health related matter relative to use of cannabis under this chapter.
V. The board may add or remove qualifying medical conditions under RSA 126-X:1, IX based on the findings of subparagraph IV(a) and after receiving input from the public through a public hearing process.
VI. The board shall maintain communications with the therapeutic advisory council established in RSA 126-X:9.
VII. On or before January 1 of each year, the board shall make a report to the president of the senate, the speaker of the house of representatives, and the chairpersons of the house and senate standing committees having jurisdiction over health and human services issues.
5 Effective Date. This act shall take effect 60 days after its passage.